Lepu Biopharma Co., Ltd. (HKG:2157)
Hong Kong · Delayed Price · Currency is HKD 7.53
-0.02 (-0.26%)
Jul 29, 2025, 9:45 AM HKT
Lepu Biopharma Revenue
In the year 2024, Lepu Biopharma had annual revenue of 367.79M CNY with 63.21% growth. Lepu Biopharma had revenue of 234.51M in the half year ending December 31, 2024, with 1,405.98% growth.
Revenue
367.79M CNY
Revenue Growth
+63.21%
P/S Ratio
34.81
Revenue / Employee
738.54K CNY
Employees
498
Market Cap
13.62B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 367.79M | 142.44M | 63.21% |
| Dec 31, 2023 | 225.35M | 209.78M | 1,347.16% |
| Dec 31, 2022 | 15.57M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| WuXi Biologics | 19.87B |
| Sino Biopharmaceutical | 30.72B |
| CSPC Pharmaceutical Group | 28.99B |